464:(i.t.) injection in immunocompetent liver cancer model in rabbits over 7 weeks, it was found that the i.t. treatment reduced the average primary tumor volume from 425 cm in control animals to 20 cm in i.t.-treated animals, and to 35 cm in the i.v. treatment group. Furthermore, the average number of lung metastases was reduced from 17 in control animals to 0.5 in i.t.-treated animals and none in the i.v.-treated animals.
24:
645:
Breitbach C.J.; Burke J.; Jonker D.; Stephenson J.; Haas A.R.; Chow L.Q.M.; Nieva J.; Hwang T.H.; Moon A.; Patt R.; Pelusio A.; Le Boeuf F.; Burns J.; Evgin L.; De Silva N.; Cvancic S.; Robertson T.; Je J.-E.; Lee Y.-S.; Parato K.; Diallo J.-S.; Fenster A.; Daneshmand M.; Bell J.C.; Kirn D.H. (2011).
376:
is produced from the JX-594 genome following infection, inducing immune response against both the virus and the tumor and enabling lasting tumor immunity. Finally, JX-594 reduces nutrient supply to tumors through blood vessel destruction. Because JX-594 is based on the Wyeth strain vaccinia virus
476:
into the tumor was observed following intratumoral injection of JX-594. Despite the presence of anti-vaccinia antibodies, virally encoded GM-CSF mRNA was detected at injection sites up to 31 weeks following the intratumoral JX-594 inoculation and was not present in the serum. Systemic GM-CSF was
496:(3 weekly i.v. doses of 10 PFU) showed that JX-594 was well tolerated, and no toxicologically significant effects were observed. There were no overt clinical signs, with the exception of ~5% of body weight loss by day 6 that was followed by a recovery by day 33.
522:
Jennerex has partnered with
Transgene, Green Cross, Lee's Pharmaceuticals, Rex Medical, and SillaJen for JX-594 development and commercialization. As of October 9, 2012, Jennerex has not licensed rights for JX-594 in either the United States or Japan.
992:
Mastrangelo M.J.; Maguire M.C.J.; Eisenlohr L.C.; Laughlin C.E.; Monken C.E.; McCue P.A; Kovatich A.J.; Lattime E.C. (1999). "Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma".
509:
Novel oncolytic viruses in
Jennerex pipeline are engineered through the Selective Oncolytic Vaccinia Engineering (SOLVE) platform. This platform is used to optimize virus targeting to specific cancer types, to select
1171:
1166:
1161:
888:
434:
394:
373:
352:
Pexa-Vec is an engineered oncolytic virus that selectively destroys cancer cells and induces tumor immune response. Uncontrolled cell division, inactivation of the
183:, and (3) reduce tumor nutrient supply through the destruction of blood vessels, Jennerex aimed to create a novel approach to treating and possibly curing cancer.
1156:
216:
913:
847:
220:
1043:
Kim J.H.; Oh J.Y.; Park B.H.; Lee D.E.; Kim J.S.; Park H.E.; Roh M.S.; Je J.E.; Yoon J.H.; Thorne S.H.; Kirn D.; Hwang T.H. (2006).
208:
28:
933:
357:
449:
Initially, it was demonstrated that patients with refractory melanomas who received intratumoral injection of JX-594 (10-2x10
514:
to include into the viral genome, and to optimize viral infection and/or replication selectivity through targeted mutations.
1086:
691:
309:
1112:
562:
313:
279:
597:
867:
289:
1045:"Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF"
957:
326:. SillaJen acquires Jennerex, Inc. SillaJen changed its name after the acquisition to SillaJen Biotherapeutics.
792:
493:
212:
368:. These features enable rapid replication of the JX-594 virus and lysis of the host cancer cells. Deletion of
180:
489:
259:
453:/lesion; 10-8x10 PFU/session for 6 weeks) had mixed (3/7), partial (1/7), or complete (1/7) responses.
372:(TK) from the JX-594 genome prevents virus replication in normal cells. The immunostimulatory cytokine
113:
171:
and JX-929 among others. By creating oncolytic viruses that can (1) kill tumor cells directly through
818:
766:
995:
457:
450:
461:
673:
438:
406:
49:
1068:
1049:
1012:
748:
665:
889:"Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)"
868:"Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)"
1058:
1004:
738:
730:
657:
648:
646:"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans".
430:
418:
369:
196:
161:
377:
that is commonly used for vaccination, it is well tolerated by rats, rabbits, and humans.
176:
165:
158:
39:
23:
477:
detected up to 7 weeks following both intratumoral and intravenous injection of JX-594.
356:
pathway that is necessary to defend against viral infections, and constitutively active
743:
718:
426:
335:
236:
154:
70:
1150:
361:
192:
92:
82:
59:
734:
677:
302:. Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer.
1090:
1063:
1044:
485:
365:
317:
293:
244:
695:
353:
86:
1116:
511:
1072:
1016:
1008:
752:
669:
569:
433:
from the JX-594 genome restricts viral replication to tumor cells, whereas
796:
269:
661:
601:
228:
961:
532:
473:
386:
347:
232:
224:
168:
240:
172:
413:; driven by the p7.5 early/late promoter) were inserted into the
175:, (2) activate the immune system by delivering genes that encode
770:
719:"Edward Jenner and the history of smallpox and vaccination"
1140:
623:
437:
production facilitates tumor immune response against, and
142:
987:
985:
983:
981:
979:
334:
Oncolytic viruses developed by
Jennerex are based on the
1172:
Technology companies based in the San
Francisco Bay Area
934:"SillaJen changes its name to mark Jennerex acquisition"
914:"SillaJen Announces Agreement to Acquire Jennerex, Inc"
848:"Search of: JX-594 - List Results - ClinicalTrials.gov"
592:
590:
1167:
Defunct pharmaceutical companies of the United States
842:
840:
838:
1087:"JX-Next Generation description on Jennerex website"
492:and resolve within 24 hours. Toxicology studies in
138:
128:
120:
109:
99:
76:
65:
55:
45:
35:
1038:
1036:
1034:
1032:
1030:
1028:
1026:
598:"Company contact information on Jennerex website"
401:; driven by a synthetic early/late promoter) and
557:
555:
553:
551:
549:
547:
488:following intratumoral injection are limited to
395:granulocyte macrophage colony-stimulating factor
215:and manufacturing operations are located at the
8:
1162:Biotechnology companies of the United States
723:Baylor University Medical Center Proceedings
219:Mission Bay campus in San Francisco, at the
16:
1113:"Company partnerships on Jennerex website"
364:signaling pathway, are common features of
22:
15:
1062:
742:
441:is included for virus tracking purposes.
958:"JX-594 description on Jennerex website"
543:
472:Dense infiltration of with CD4 and CD8
425:) in the J segment of the Wyeth strain
191:Jennerex received its name in honor of
460:(i.v.) delivery of JX-594 (10 PFU) to
179:and by overcoming tumor cell-induced
7:
282:Phase 2a clinical trial (HEP007).
221:Ottawa Hospital Research Institute
14:
272:Phase 1 clinical trial (HEP001).
209:Financial District, San Francisco
29:Financial District, San Francisco
1157:Companies based in San Francisco
292:(EMA) designated Pexa-Vec as an
207:Headquarters are located in the
199:and "the father of immunology".
81:450 Sansome Street, 16th Floor,
563:"Jennerex facts sheet: Q3 2012"
819:"Jennerex Biotherapeutics Inc"
735:10.1080/08998280.2005.11928028
151:Jennerex Biotherapeutics, Inc.
1:
887:France, Kelly (May 8, 2013).
767:"Edward Jenner (1749 - 1823)"
105:4 (USA, Canada, South Korea)
1064:10.1016/j.ymthe.2006.05.008
164:company that developed the
1188:
345:
494:New Zealand White rabbits
290:European Medicines Agency
21:
773:: Historic Figures. 2012
262:, USA) was established.
938:www.thepharmaletter.com
181:immunological tolerance
1115:. 2012. Archived from
1089:. 2012. Archived from
1009:10.1038/sj.cgt.7700066
960:. 2012. Archived from
795:. 2012. Archived from
694:. 2012. Archived from
600:. 2012. Archived from
568:. 2012. Archived from
1119:on September 26, 2012
1093:on September 27, 2012
278:. Jennerex initiated
268:. Jennerex completed
195:, the pioneer of the
964:on November 17, 2012
575:on February 28, 2013
996:Cancer Gene Therapy
799:on February 2, 2013
698:on January 15, 2013
662:10.1038/nature10358
456:Upon comparison of
130:Number of employees
101:Number of locations
18:
793:"SillaJen website"
717:Riedel S. (2005).
624:"Jennerex website"
604:on August 22, 2012
505:JX-Next Generation
258:. Jennerex, Inc. (
157:) was an American
50:Biopharmaceuticals
1050:Molecular Therapy
823:BioCentury – BCIQ
692:"Jenner-ex story"
490:flu-like symptoms
429:. Elimination of
342:Pexa-Vec (Jx-594)
296:for Live Cancer.
166:oncolytic viruses
162:biopharmaceutical
148:
147:
114:Pexa-Vec (JX-594)
1179:
1129:
1128:
1126:
1124:
1109:
1103:
1102:
1100:
1098:
1083:
1077:
1076:
1066:
1040:
1021:
1020:
989:
974:
973:
971:
969:
954:
948:
947:
945:
944:
930:
924:
923:
921:
920:
910:
904:
903:
901:
899:
893:marketwired.com/
884:
878:
877:
875:
874:
864:
858:
857:
855:
854:
844:
833:
832:
830:
829:
815:
809:
808:
806:
804:
789:
783:
782:
780:
778:
763:
757:
756:
746:
714:
708:
707:
705:
703:
688:
682:
681:
656:(7362): 99–102.
642:
636:
635:
633:
631:
620:
614:
613:
611:
609:
594:
585:
584:
582:
580:
574:
567:
559:
419:thymidine kinase
370:thymidine kinase
197:smallpox vaccine
177:immunostimulants
143:www.sillajen.com
26:
19:
1187:
1186:
1182:
1181:
1180:
1178:
1177:
1176:
1147:
1146:
1137:
1132:
1122:
1120:
1111:
1110:
1106:
1096:
1094:
1085:
1084:
1080:
1042:
1041:
1024:
991:
990:
977:
967:
965:
956:
955:
951:
942:
940:
932:
931:
927:
918:
916:
912:
911:
907:
897:
895:
886:
885:
881:
872:
870:
866:
865:
861:
852:
850:
846:
845:
836:
827:
825:
817:
816:
812:
802:
800:
791:
790:
786:
776:
774:
765:
764:
760:
716:
715:
711:
701:
699:
690:
689:
685:
644:
643:
639:
629:
627:
622:
621:
617:
607:
605:
596:
595:
588:
578:
576:
572:
565:
561:
560:
545:
541:
529:
527:Further reading
520:
507:
502:
483:
470:
468:Immune response
447:
417:gene (encoding
407:β-galactosidase
405:gene (encoding
393:gene (encoding
383:
350:
344:
332:
253:
251:Company History
205:
189:
131:
102:
95:
89:
31:
17:Jennerex , Inc.
12:
11:
5:
1185:
1183:
1175:
1174:
1169:
1164:
1159:
1149:
1148:
1145:
1144:
1136:
1135:External links
1133:
1131:
1130:
1104:
1078:
1057:(3): 361–370.
1022:
1003:(5): 409–422.
975:
949:
925:
905:
879:
859:
834:
810:
784:
758:
709:
683:
637:
615:
586:
542:
540:
537:
536:
535:
528:
525:
519:
516:
506:
503:
501:
498:
482:
479:
469:
466:
446:
443:
427:vaccinia virus
382:
379:
346:Main article:
343:
340:
336:vaccinia virus
331:
328:
252:
249:
204:
201:
188:
185:
153:(now owned by
146:
145:
140:
136:
135:
132:
129:
126:
125:
124:SillaJen, Inc.
122:
118:
117:
111:
107:
106:
103:
100:
97:
96:
91:
80:
78:
74:
73:
71:SillaJen, Inc.
67:
63:
62:
57:
53:
52:
47:
43:
42:
37:
33:
32:
27:
13:
10:
9:
6:
4:
3:
2:
1184:
1173:
1170:
1168:
1165:
1163:
1160:
1158:
1155:
1154:
1152:
1142:
1139:
1138:
1134:
1118:
1114:
1108:
1105:
1092:
1088:
1082:
1079:
1074:
1070:
1065:
1060:
1056:
1052:
1051:
1046:
1039:
1037:
1035:
1033:
1031:
1029:
1027:
1023:
1018:
1014:
1010:
1006:
1002:
998:
997:
988:
986:
984:
982:
980:
976:
963:
959:
953:
950:
939:
935:
929:
926:
915:
909:
906:
894:
890:
883:
880:
869:
863:
860:
849:
843:
841:
839:
835:
824:
820:
814:
811:
798:
794:
788:
785:
772:
768:
762:
759:
754:
750:
745:
740:
736:
732:
728:
724:
720:
713:
710:
697:
693:
687:
684:
679:
675:
671:
667:
663:
659:
655:
651:
650:
641:
638:
625:
619:
616:
603:
599:
593:
591:
587:
579:September 23,
571:
564:
558:
556:
554:
552:
550:
548:
544:
538:
534:
531:
530:
526:
524:
517:
515:
513:
504:
499:
497:
495:
491:
487:
480:
478:
475:
474:T lymphocytes
467:
465:
463:
459:
454:
452:
444:
442:
440:
436:
432:
428:
424:
420:
416:
412:
408:
404:
400:
396:
392:
388:
380:
378:
375:
371:
367:
363:
359:
355:
349:
341:
339:
337:
329:
327:
325:
321:
319:
315:
311:
307:
303:
301:
297:
295:
291:
287:
283:
281:
277:
273:
271:
267:
263:
261:
260:San Francisco
257:
250:
248:
246:
242:
238:
237:SillaJen, Inc
234:
230:
226:
222:
218:
214:
210:
202:
200:
198:
194:
193:Edward Jenner
186:
184:
182:
178:
174:
170:
167:
163:
160:
156:
152:
144:
141:
137:
133:
127:
123:
119:
115:
112:
108:
104:
98:
94:
88:
84:
83:San Francisco
79:
75:
72:
68:
64:
61:
60:David H. Kirn
58:
54:
51:
48:
44:
41:
38:
34:
30:
25:
20:
1121:. Retrieved
1117:the original
1107:
1095:. Retrieved
1091:the original
1081:
1054:
1048:
1000:
994:
966:. Retrieved
962:the original
952:
941:. Retrieved
937:
928:
917:. Retrieved
908:
896:. Retrieved
892:
882:
871:. Retrieved
862:
851:. Retrieved
826:. Retrieved
822:
813:
801:. Retrieved
797:the original
787:
777:September 9,
775:. Retrieved
761:
729:(1): 21–25.
726:
722:
712:
702:September 9,
700:. Retrieved
696:the original
686:
653:
647:
640:
630:September 9,
628:. Retrieved
618:
606:. Retrieved
602:the original
577:. Retrieved
570:the original
521:
518:Partnerships
508:
486:Side effects
484:
471:
462:intratumoral
455:
448:
422:
414:
410:
402:
398:
390:
385:To engineer
384:
366:cancer cells
351:
333:
323:
322:
305:
304:
299:
298:
285:
284:
275:
274:
265:
264:
255:
254:
206:
190:
150:
149:
77:Headquarters
69:acquired by
36:Company type
458:intravenous
318:orphan drug
312:designated
294:orphan drug
245:South Korea
1151:Categories
1123:October 9,
1097:October 8,
968:October 2,
943:2020-06-24
919:2018-06-17
873:2018-06-17
853:2018-06-17
828:2018-06-17
803:October 8,
608:October 8,
539:References
512:transgenes
354:interferon
223:(OHRI) in
87:California
235:, and at
203:Locations
1143:homepage
1141:Jennerex
1073:16905462
1017:10505851
898:June 16,
753:16200144
670:21886163
445:Efficacy
389:, human
330:Pipeline
314:Pexa-Vec
280:Pexa-Vec
270:Pexa-Vec
155:SillaJen
116:, JX-929
110:Products
46:Industry
744:1200696
678:4365604
229:Ontario
213:R&D
187:Company
159:private
139:Website
56:Founder
40:Private
1071:
1015:
751:
741:
676:
668:
649:Nature
626:. 2012
533:JX-594
500:JX-929
481:Safety
435:GM-CSF
399:GM-CSF
387:JX-594
381:Design
374:GM-CSF
348:JX-594
316:as an
233:Canada
225:Ottawa
169:JX-594
674:S2CID
573:(PDF)
566:(PDF)
439:β-gal
411:β-gal
391:GMCSF
308:. US
241:Busan
239:. in
173:lysis
121:Owner
1125:2012
1099:2012
1069:PMID
1013:PMID
970:2012
900:2018
805:2012
779:2012
749:PMID
704:2012
666:PMID
632:2012
610:2012
581:2012
403:lacZ
358:EGFR
324:2014
306:2013
300:2011
286:2009
276:2008
266:2007
256:2003
217:UCSF
93:U.S.
66:Fate
1059:doi
1005:doi
771:BBC
739:PMC
731:doi
658:doi
654:477
451:PFU
421:or
409:or
397:or
362:Ras
310:FDA
134:~50
1153::
1067:.
1055:14
1053:.
1047:.
1025:^
1011:.
999:.
978:^
936:.
891:.
837:^
821:.
769:.
747:.
737:.
727:18
725:.
721:.
672:.
664:.
652:.
589:^
546:^
431:TK
423:TK
415:TK
338:.
320:.
288:.
247:.
243:,
231:,
227:,
211:.
90:,
85:,
1127:.
1101:.
1075:.
1061::
1019:.
1007::
1001:6
972:.
946:.
922:.
902:.
876:.
856:.
831:.
807:.
781:.
755:.
733::
706:.
680:.
660::
634:.
612:.
583:.
360:-
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
